Discontinued drugs in 2005: endocrine and metabolic

Abstract

This perspective describes the compounds from the endocrine and metabolic area that were discontinued during the calendar year 2005. This is a continuation of a series of perspectives of each of the editorial areas summarized by Expert Opinion on Investigational Drugs. The candidates for this summary were being developed in the areas of treatment of diabetes and diabetes complications, as well as reproductive and urogenital heath issues.

Keywords::

• diabetes
• diabetes complications
• endometriosis
• FK-614
• hypogonadism
• LY-929
• overactive bladder
• TAK-559